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Summary
Background: Group B Streptococcus (GBS) is a significant cause of invasive disease among adult non-pregnant 
patients with increasing incidence and mortality rates. Although non-alcoholic fatty liver disease (NAFLD) is associated 
with components of metabolic syndrome previously recognized as risk factors for GBS, the impact of NAFLD on GBS 
course and outcomes is unknown.
Methods: We conducted a retrospective cohort study of all non-pregnant adult patients diagnosed with invasive GBS 
infection during a 15-year period.
Results: 102 patients were included in the study (46.1% males; median age 69, IQR 58-78 years). Disease primarily 
presented as bacteremia without a defined source (37; 36.3%), cellulitis/erysipelas (35; 34.3%), pneumonia (13; 
12.7%) and endocarditis (8; 7.8%). The most common comorbidities were diabetes (42; 41.2%), dyslipidemia (39; 
38.2%), cardiovascular disease (34; 33.3%), peripheral vascular disease (21; 20.6%), obesity (21; 20.6%) and ma-
lignancy (10; 9.8%). Based upon the results of abdominal ultrasound, the patients were divided into two groups: the 
ones with steatosis (44; 43.1%) and the ones without steatosis (58; 56.9%). There were no significant differences in 
clinical presentations and comorbidities between groups. In-hospital mortality was 29.5% (13/44) in patients with 
NAFLD and 10.3% (6/58) in the control group (p=0.0200). Endocarditis (OR 6.69; 95%CI 1.045-44.46, p=0.0410), 
acute renal failure (OR 13.92; 95%CI 3.00-77.71, p=0.0013), qSOFA > 2 (OR 23.93; 95%CI 4.66-171.2) and NAFLD 
(OR 6.64; 95%CI 1.23-47.88, p=0.0258) were independently associated with in-hospital mortality.
Conclusions: NAFLD is associated with higher mortality in patients suffering from invasive GBS disease which ap-
pears to be independent of other components of the metabolic syndrome, such as obesity and diabetes mellitus.
Sažetak
Uvod: Streptokok grupe B (GBS) značajan je uzrok invazivne bolesti kod odraslih bolesnika s porastom incidencije 
i smrtnosti. Iako je nealkoholna masna bolest jetre – NAFLD (engl. non-alcoholic fatty liver disease) povezana s 
komponentama metaboličkog sindroma koji su prepoznati kao čimbenici rizika za GBS, utjecaj NAFLD na tijek i 
ishode invazivne GBS bolesti još uvijek nije poznat.
Metode: Proveli smo retrospektivno kohortno istraživanje svih odraslih bolesnika koji nisu trudni, a kojima je 
dijagnosticirana invazivna GBS infekcija tijekom 15-godišnjeg razdoblja.
Rezultati: U istraživanje je uključeno 102 bolesnika (46,1% muškaraca; srednja dob 69, IQR 58-78 godina). Bo-
lest se primarno prezentirala kao bakterijemija nepoznatog ishodišta (37; 36,3%), celulitis/erizipel (35; 34,3%), 
pneumonija (13; 12,7%) i endokarditis (8; 7,8%). Najčešći komorbiditeti bili su dijabetes (42; 41,2%), dislipide-
mija (39; 38,2%), kardiovaskularne bolesti (34; 33,3%), periferne vaskularne bolesti (21; 20,6%), pretilost (21; 
20,6%) i maligna bolest (10; 9,8%). Prema nalazu ultrazvuka abdomena, bolesnici su podijeljeni u dvije skupine: 
bolesnici s NAFLD (44; 43,1%) i bolesnici bez steatoze jetre (58; 56,9%). Nije bilo značajnih razlika u kliničkoj 
prezentaciji i komorbiditetima među skupinama. Smrtnost za vrijeme hospitalizacije iznosila je 29,5% (13/44) 
kod bolesnika s NAFLD i 10,3% (6/58) u kontrolnoj skupini (p = 0,0200). Endokarditis (OR 6,69; 95% CI 1,045-
44,46, p = 0,0410), akutno zatajenje bubrega (OR 13,92; 95% CI 3,00-77,71, p = 0,0013), qSOFA> 2 (OR 23,93; 
95% CI 4,66-171,2) i NAFLD (OR 6,64; 95% CI 1,23-47,88, p = 0,0258) bili su neovisno povezani sa smrtnošću.
Zaključci: NAFLD je povezan s većom smrtnošću kod bolesnika s invazivnom GBS bolešću i čini se da je to neovi-
sno o drugim komponentama metaboličkog sindroma, kao što su pretilost i dijabetes melitus.
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also serves as the national referral centre for infectious 
diseases. We reviewed the hospital records of all con-
secutive non-pregnant adult patients diagnosed with 
invasive GBS infection (GBS isolated from normally 
sterile site) hospitalized in a 15-year period (2005-
2019). Of the 139 patients suffering from invasive GBS 
during the period studied, 102 met inclusion criteria 
and were included in the study (47, 46.1% males; me-
dian age 69, IQR 58-78 years).
 Data Collection, Outcomes, and Definitions
 Demographic data, comorbidities (measured by 
age adjusted for Charlson Comorbidity Index, CCI), 
the presenting infectious syndrome, antimicrobial 
therapy, treatment duration, length of hospital stay, 
complications and outcomes were collected from the 
patients’ charts.
 The following blood laboratory data from the ad-
mission were analysed: C-reactive protein level (CRP), 
white blood cell count (WBC), platelet count (Plt), 
coagulation parameters, aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), blood urea 
nitrogen (BUN), serum creatinine and serum albumin 
concentration. APRI and FIB-4 score were calculated 
for all patients and were used as a surrogate marker of 
liver injury[13, 14].
 Diagnosis of NAFLD was based on the presence of 
fatty liver by ultrasonography (US) and by the absence 
of secondary cause of liver steatosis (e.g. chronic vi-
ral hepatitis, Wilson’s disease, autoimmune hepatitis, 
alcohol intake)[1]. The study protocol conforms to the 
ethical guidelines of the 1975 Declaration of Helsinki 
(6th revision, 2008) as reflected in a priori approval by 
the institution's human research committee.
 Statistical Analysis
 The demographic, clinical characteristics, and lab-
oratory data were evaluated and presented descrip-
tively. Fisher’s exact test and the Mann-Whitney U 
test were used to compare the groups, as appropriate. 
All tests were two-tailed; p < 0.05 was considered sta-
tistically significant. Binary logistic regression analy-
sis was used to assess the independent predictors of 
in-hospital mortality. All variables were entered in a 
backward stepwise logistic regression model. Statisti-
cally non-significant predictors were progressively ex-
cluded based on a likelihood ratio test. The strength 
of association was expressed as odds ratio (OR) and 
its corresponding 95% confidence intervals (95% CI). 
Statistical analyses were performed using the MedCalc 
for Windows®, ver. 19.0.7 (MedCalc Software, Mariak-
erke, Belgium).
Introduction
 Non-alcoholic fatty liver disease (NAFLD) and its 
role in bacterial infections have only recently begun to 
be revealed. NAFLD represents a spectrum of chronic 
liver diseases ranging from simple steatosis to non-al-
coholic steatohepatitis (NASH), cirrhosis, and hepa-
tocellular carcinoma[1]. NAFLD is associated with the 
components of metabolic syndrome, primarily diabe-
tes mellitus and obesity[1]. There are cumulative data 
that NAFLD is associated with systemic changes in the 
immune response that might have profound effect on 
infection course and outcome[2].
 The liver dysfunction in sepsis in patients without 
pre-existing liver disease is an independent predictor 
of mortality[3]. The risk of developing bacterial infec-
tions is even more increased in patients suffering from 
liver cirrhosis, making them ten times more suscep-
tible to bloodstream infections resulting in a fourfold 
increase in mortality[4]. There are only several clinical 
studies that examined the role of NAFLD in bacterial 
infections. NAFLD was associated with an increase in 
all-cause mortality in patients suffering from commu-
nity-acquired pneumonia[5]. Bacteraemia of gastroin-
testinal origin and recurrent urinary tract infections 
were more common in patients with NAFLD[6, 7]. More 
recently, NAFLD was identified as a risk factor for 
Clostridioides difficile infection[8].
 However, to the best of our knowledge, there are no 
data on the association of group B Streptococcus (GBS) 
diseases in patients with NAFLD. Group B Strepto-
coccus is a significant cause of invasive disease among 
adult non-pregnant patients with increasing incidence 
and high mortality rates[9]. This is highlighted in the 
large USA surveillance study, where the incidence of 
invasive GBS disease among non-pregnant adults tri-
pled in the last 25 years and in 2016 was higher than 
the rate of invasive pneumococcal disease in adults[9].
 GBS is a pathobiont that is often part of the normal 
microbiota of the human gastrointestinal tract and rare-
ly causes invasive disease. There is a plethora of studies 
which attempted to characterize the adults most sus-
ceptible to invasive GBS infection. While obesity and 
diabetes are most common underlying conditions asso-
ciated with substantially increased risk of infection and 
mortality[10-12], the role of NAFLD with GBS invasive 
disease outcomes has not been investigated.
Methods
 Study Design and Patients
 This was a retrospective cohort study conducted 
at the University Hospital for Infectious Diseases „Dr. 
Fran Mihaljević” in Zagreb, Croatia (UHID), which 
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ries: 10 (22.7%) with high risk FIB-4 (FIB-4> 3.25), 12 
(27.2%) with intermediate-risk FIB-4 (1.45 <FIB-4 > 
3.25) and 22 (50%) with low risk FIB-4 (FIB-4> 1.45). 
Moreover, the presence of intermediate/high risk FIB-
4 as well as the presence of liver cirrhosis were not as-
sociated with adverse outcomes in the NAFLD cohort.
 The median duration of hospitalization was 14 (IQR 
11-19) days in NAFLD and 12.5 (IQR 8.75-16.7) in non-
NAFLD group (p=0.5961). Overall, 41 patients (40.2%) 
developed complications during hospitalization and 
24 (23.5%) were admitted to the intensive care unit 
(ICU). Nosocomial infections (12, 27.3% vs. 6, 10.3%; 
p=0.0359) and acute renal failure (9, 20.5% vs. 3, 5.2%; 
p=0.0276) were more common in the NAFLD group.
 In-hospital mortality was 29.5% (13/44) in patients 
with NAFLD and 10.3% (6/58) in the control group 
(p=0.0200). To determine whether NAFLD was inde-
pendently associated with in-hospital mortality, we 
performed a multivariate logistic regression analysis. 
After adjustment for potential cofounders, endocar-
ditis (OR 6.69; 95%CI 1.045-44.46, p=0.0410), acute 
renal failure (OR 13.92; 95%CI 3.00-77.71, p=0.0013), 
qSOFA ≥ 2 (OR 23.93; 95%CI 4.66-171.2) and NAFLD 
(OR 6.64; 95%CI 1.23-47.88, p=0.0258) were inde-
pendently associated with in-hospital mortality. Inter-
estingly, diabetes mellitus and obesity were not associ-
ated with mortality in our model.
Results
 Disease primarily presented as bacteraemia with-
out a defined source (37; 36.3%), cellulitis/erysipelas 
(35; 34.3%), pneumonia (13; 12.7%) and endocarditis 
(8; 7.8%). The most common comorbidities were diabe-
tes (42; 41.2%), dyslipidaemia (39; 38.2%), cardiovascu-
lar disease (34; 33.3%), peripheral vascular disease (21; 
20.6%), obesity (21; 20.6%) and malignancy (10; 9.8%). 
Based upon the results of abdominal US the patients 
were divided into two groups: with steatosis (44; 43.1%) 
and without steatosis (58; 56.9%). There were no signifi-
cant differences in clinical presentations and comorbid-
ities between groups, as presented in Table 1.
 On admission, the majority of patients had a qSO-
FA score of 0 or 1 (83; 81.4%), even though 80 patients 
(78.4%) had ≥ 2 SIRS criteria; all patients had elevated 
CRP (median of 111 mg/L, IQR 32-170). Patients with 
NAFLD were younger (65, IQR 58-73 vs. 75, IQR 62-
82 years, p=0.01), had higher AST (45.0; IQR 30-71 vs. 
28.5; IQR 20-71, p=0.047) and ALT (38; 25.5-55.5 vs. 
21.5; 14-40, p=0.009) than non-NAFLD group. There 
were no significant differences in other laboratory re-
sults on admission (CRP, BUN, creatinine, haemoglo-
bin, leukocytes, Plt and coagulation).
 Fibrosis index-4 (FIB-4) was calculated on blood 
tests on the admission date, and according to FIB-4 
values, the NAFLD group was stratified into 3 catego-
Table 1. Clinical characteristics of patients with invasive Group B streptococcus disease
Tablica 1. Kliničke karakteristike bolesnika oboljelih od invazivne bolesti uzrokovane streptokokom grupe B
Liver steatosis 
(n=44)
No liver steatosis 
(n=58) P-value 
a
Male sex 24 (54.5%) 23 (39.7%) 0.1625
Age, year (median, IQRb) 65 (58-73) 75 (62-82) 0.0127
Long-term facility resident 4 (9.1%) 7 (12.1%) 0.7533
Comorbidities
Diabetes mellitus 23 (52.3%) 19 (32.8%) 0.0672
Dyslipidaemia 21 (47.7%) 18 (31.0%) 0.1022
Cardiovascular disease 18 (40.9%) 16 (27.6%) 0.2039
Peripheral vascular disease 12 (27.3%) 9 (15.5%) 0.2159
Obesity 13 (29.5%) 8 (13.8%) 0.0820
Malignancy 6 (13.6%) 10 (17.2%) 0.7849
Chronic renal disease 5 (11.4%) 5 (8.6%) 0.7420
COPD/asthma 4 (9.1%) 5 (8.6%) 1.0000
Neurological diseases 11 (25.0%) 9 (15.5%) 0.3145
Clinical syndrome
Primary bacteraemia without a defined source 17 (38.6%) 20 (34.5%) 0.6829
Skin infection 15 (34.1%) 20 (34.5%) 1.0000
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 Notably, no previous study examined the associ-
ation of NAFLD with GBS. The possible explanation 
of increased risk of invasive GBS disease and high 
mortality rates in NAFLD patients may include higher 
GBS colonization due to the changes in gut microbi-
ome, and the impairment of gut and systemic immune 
response, the pathophysiology of which is largely un-
der-investigated[2]. NAFLD is now considered a mul-
tisystem disease with significant impact on the innate 
and adaptive immune responses. A complex crosstalk 
between the gut, adipose tissue and the liver, as well 
as the changes in expression of cytokines, adipokines 
and cells of the immune system which drives the dis-
eases progression and might have significant impact to 
the systemic response to infection, sepsis course and 
outcome. For example, it was shown that patients with 
NAFLD have higher serum concentrations of common 
inflammatory biomarkers, such as C-reactive protein 
(CRP) and interleukins (specifically IL6, IL17, leptins, 
TNF-α and TGF-β), which correlate with the progno-
sis of NAFLD[17]. Moreover, a recently described high-
ly proinflammatory Th-17 response present in patients 
with NAFLD might unbalance pro-inflammatory and 
anti-inflammatory response necessary for bacterial 
clearance and resolution of inflammation to promote 
recovery from sepsis[18, 19].
 The major limitation of this study comes from its 
retrospective design; the diagnosis of NAFLD was 
based on abdominal US and patients were not sys-
tematically screened for other causes of liver steatosis, 
except from data available in medical charts. Further-
more, the diagnosis of liver steatosis in our cohort 
might be underdiagnosed, since smaller percentage 
Discussion
 The incidence of GBS invasive disease among adult 
non-pregnant patients has been rising for several dec-
ades, and adults now account for nearly 90% of all in-
vasive GBS diseases[9]. The well-defined risk factors for 
invasive GBS disease include elderly age and compo-
nents of the metabolic syndrome; obesity and diabe-
tes[10-12]. In addition, both diabetes mellitus and obesity 
were also shown to be independently associated with 
higher rates of group B streptococcal colonization[15].
 We have provided the first evidence that invasive 
GBS disease in patients with NAFLD is associated with 
higher mortality than in patients without NAFLD. 
Moreover, this appears to be independent of other 
components of metabolic syndrome, such as obesity 
and diabetes mellitus. Furthermore, nosocomial infec-
tions and acute renal failure were more common in the 
NAFLD group, which highlights the impact of NAFLD 
on disease outcome. Since a significant proportion of 
our cohort (43%) had liver steatosis, NAFLD could be 
considered as a risk factor for invasive GBS disease.
 Patients with NAFLD might be particularly suscep-
tible to severe disease as they carry a particular combi-
nation of previously mentioned risk factors. Firstly, the 
presence of type-2 diabetes confers susceptibility to 
infection and incidence of invasive GBS infections is 
even more increased among patients with poor glycae-
mic control[10-12]. Secondly, considering a high preva-
lence of cardiovascular disease, patients with NAFLD 
may show a decreased cardiac reserve that might be 
associated with increased mortality. Both obesity and 
diabetes are associated with changes in skin barrier 
function or alteration of immune function[16].
Pneumonia 5 (11.4%) 8 (13.8%) 0.7731
Endocarditis 3 (6.8%) 5 (8.6%) 1.0000
Osteoarticular infection 2 (4.5%) 2 (3.4%) 1.0000
Urinary tract infection 1 (2.3%) 2 (3.4%) 1.0000
CNS infection (meningitis) 1 (2.3%) 1 (1.7%) 1.0000
Clinical Course and Outcomes
Duration of hospitalization 14 (11-19) 12,5 (8,75-16,7) 0.5961
In-hospital mortality 13 (29.5%) 6 (10.3%) 0.0200
ICU admissionc 14 (31.8%) 10 (17.2%) 0.1024
Mechanical ventilation 13 (29.5%) 8 (13.8%) 0.0820
Nosocomial infection 12 (27.3%) 6 (10.3%) 0.0359
Acute renal failure 9 (20.5%) 3 (5.2%) 0.0276
Heart failure 8 (18.2%) 4 (6.9%) 0.1198
Other 7 (15.9%) 7 (12.1%) 0.5779
a Fisher exact or Mann-Whitney U test, as appropriate; b IQR, interquartile range; c ICU, intensive care unit
128
Non-Alcoholic Fatty Liver Disease is Associated with an Increased Mortality in Adult Patients with Group B Streptococcus Invasive Disease    Branimir Gjurašin et al.    INFEKTOL GLASN 2020;40(4):124-128
 [6] Nseir W, Amara A, Farah R, Ahmad HS, Mograbi J, Maha-
mid M. Non-alcoholic Fatty Liver Disease is Associated with 
Recurrent Urinary Tract Infection in Premenopausal Wom-
en Independent of Metabolic Syndrome. Isr Med Assoc J. 
2019;21(6):386-9.
 [7] Nseir W, Artul S, Nasrallah N, Mahamid M. The association 
between primary bacteraemia of presumed gastrointestinal 
origin and non-alcoholic fatty liver disease. Dig Liver Dis. 
2016;48(3):343-4.
 [8] Papic N, Jelovcic F, Karlovic M, Maric LS, Vince A. Non-alco-
holic fatty liver disease as a risk factor for Clostridioides diffi-
cile infection. Eur J Clin Microbiol Infect Dis. 2020;39(3):569-
74.
 [9] Francois Watkins LK, McGee L, Schrag SJ, et al. Epidemiol-
ogy of Invasive Group B Streptococcal Infections Among 
Non-pregnant Adults in the United States, 2008-2016. JAMA 
Intern Med. 2019;179(4):479-88.
 [10] Jump RLP, Wilson BM, Baechle D, et al. Risk Factors and Mor-
tality Rates Associated With Invasive Group B Streptococcus 
Infections Among Patients in the US Veterans Health Admin-
istration. JAMA Netw Open. 2019;2(12):e1918324.
 [11] Pitts SI, Maruthur NM, Langley GE, Pondo T, Shutt KA, Hol-
lick R, et al. Obesity, Diabetes, and the Risk of Invasive Group 
B Streptococcal Disease in Non-pregnant Adults in the United 
States. Open Forum Infect Dis. 2018;5(6):ofy030.
 [12] Park SY, Park Y, Chung JW, et al. Group B streptococcal bacte-
raemia in non-pregnant adults: results from two Korean cen-
tres. Eur J Clin Microbiol Infect Dis. 2014;33(10):1785-90.
 [13] Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-Cardenas E, 
Sanchez-Avila F, Vargas-Vorackova F. AST to platelet ratio 
index (APRI) for the non-invasive evaluation of liver fibrosis. 
Ann Hepatol. 2008;7(4):350-7,
 [14] Sumida Y, Yoneda M, Hyogo H, et al. Validation of the FIB4 in-
dex in a Japanese non-alcoholic fatty liver disease population. 
BMC Gastroenterol. 2012;12:2.
 [15] Ramos E, Gaudier FL, Hearing LR, Del Valle GO, Jenkins S, 
Briones D. Group B streptococcus colonization in pregnant 
diabetic women. Obstet Gynecol. 1997;89(2):257-60.
 [16] Fontana L, Eagon JC, Colonna M, Klein S. Impaired mononu-
clear cell immune function in extreme obesity is corrected by 
weight loss. Rejuvenation Res. 2007;10(1):41-6.
 [17] Paquissi FC. Immune Imbalances in Non-Alcoholic Fatty 
Liver Disease: From General Biomarkers and Neutrophils to 
Interleukin-17 Axis Activation and New Therapeutic Targets. 
Front Immunol. 2016;7:490.
 [18] Van Herck MA, Weyler J, Kwanten WJ, et al. The Differential 
Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obe-
sity. Front Immunol. 2019;10:82.
 [19] Sutti S, Albano E. Adaptive immunity: an emerging player in 
the progression of NAFLD. Nat Rev Gastroenterol Hepatol. 
2020;17(2):81-92.
of obese and diabetics had fatty liver than previous-
ly reported in other studies. Further, the number of 
patients with intermediate/high risk FIB-4 and es-
tablished NAFLD associated cirrhosis was probably 
insufficient to draw definitive conclusions. Although 
the study population was relatively small; we included 
consecutive patients with imaging of the liver availa-
ble or known diagnosis of NAFLD, providing a more 
reliable selection of the study cohort: NAFLD vs non-
NAFLD patients.
 In conclusion, we provide the first data on invasive 
GBS course in patients with NAFLD. This might be 
relevant for identification of adult non-pregnant pa-
tients at high risk for invasive GBS disease who might 
benefit from prophylactic measures. Importantly, the 
efficacy and immunogenicity of GBS vaccines which 
are in development for prevention of neonatal disease 
may be impacted by NAFLD in adult population. In 
addition, this highlights the need for further prospec-
tive studies to evaluate the association of NAFLD with 
the outcomes of bacterial infections.
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